Published in J Transl Med on June 23, 2014
Hallmarks of cancer: the next generation. Cell (2011) 140.01
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med (2004) 22.96
Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol (2009) 9.41
Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med (2006) 8.41
Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production. Int Immunol (2007) 5.45
Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med (2010) 4.90
Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nat Immunol (2012) 3.57
The tumor-promoting actions of TNF-alpha involve TNFR1 and IL-17 in ovarian cancer in mice and humans. J Clin Invest (2009) 2.42
CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol (2006) 2.18
A dynamic inflammatory cytokine network in the human ovarian cancer microenvironment. Cancer Res (2011) 1.55
Functional characterization of human Cd33+ and Cd11b+ myeloid-derived suppressor cell subsets induced from peripheral blood mononuclear cells co-cultured with a diverse set of human tumor cell lines. J Transl Med (2011) 1.52
Inflammation and ovarian cancer. Cytokine (2012) 1.49
Tumor-infiltrating regulatory T cells delineated by upregulation of PD-1 and inhibitory receptors. Cell Immunol (2012) 1.37
Regulatory T cell infiltration predicts outcome following resection of colorectal cancer liver metastases. Ann Surg Oncol (2012) 1.24
Phenotypic and functional characteristics of CD4+ CD39+ FOXP3+ and CD4+ CD39+ FOXP3neg T-cell subsets in cancer patients. Eur J Immunol (2012) 1.21
A cytokine profile of normal and malignant ovary. Cytokine (1996) 1.16
CRP identifies homeostatic immune oscillations in cancer patients: a potential treatment targeting tool? J Transl Med (2009) 1.15
Circadian clocks in mouse and human CD4+ T cells. PLoS One (2011) 1.13
Tumor-associated lymphocytes and increased FoxP3+ regulatory T cell frequency correlate with more aggressive papillary thyroid cancer. J Clin Endocrinol Metab (2010) 1.13
Inflammatory events in endometrial adenocarcinoma. J Endocrinol (2010) 1.06
Regulation of ovarian carcinoma SKOV-3 cell proliferation and secretion of MMPs by autocrine IL-6. Anticancer Res (2007) 0.98
Tumor microenvironment macrophage inhibitory factor directs the accumulation of interleukin-17-producing tumor-infiltrating lymphocytes and predicts favorable survival in nasopharyngeal carcinoma patients. J Biol Chem (2012) 0.98
TNF optimally activatives regulatory T cells by inducing TNF receptor superfamily members TNFR2, 4-1BB and OX40. Eur J Immunol (2011) 0.97
Localization of leukocyte subsets in the follicle wall and in the corpus luteum throughout the human menstrual cycle. Fertil Steril (1994) 0.94
Binding of C/EBPbeta to the C-reactive protein (CRP) promoter in Hep3B cells is associated with transcription of CRP mRNA. J Immunol (2008) 0.93
Expression of IL-10 in patients with ovarian carcinoma. Anticancer Res (2006) 0.93
Defining a functionally distinct subset of human memory CD4+ T cells that are CD25POS and FOXP3NEG. Eur J Immunol (2012) 0.91
Transforming growth factor-beta1 produced by ovarian cancer cell line HRA stimulates attachment and invasion through an up-regulation of plasminogen activator inhibitor type-1 in human peritoneal mesothelial cells. J Biol Chem (2003) 0.91
Fluctuation of systemic immunity in melanoma and implications for timing of therapy. Front Biosci (Elite Ed) (2012) 0.86
CD4+CD25+Foxp3+ Treg and TGF-beta play important roles in pathogenesis of Uygur cervical carcinoma. Eur J Gynaecol Oncol (2012) 0.85
T helper type 17 cells contribute to anti-tumour immunity and promote the recruitment of T helper type 1 cells to the tumour. Immunology (2013) 0.84
Pathogenic role of IL-6 combined with TNF-α or IL-1 in the induction of acute phase proteins SAA and CRP in chronic inflammatory diseases. Adv Exp Med Biol (2011) 0.84
Monocyte chemotactic protein-1 (MCP-1), its receptor, and macrophages in the perifollicular stroma during the human ovulatory process. Fertil Steril (2008) 0.82
Treatment with targeted vesicular stomatitis virus generates therapeutic multifunctional anti-tumor memory CD4 T cells. Cancer Gene Ther (2012) 0.78
Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci U S A (2002) 30.32
Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet (2010) 4.51
A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet (2010) 3.86
Longitudinal assessment of chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning. J Clin Oncol (2011) 3.69
A method for calling gains and losses in array CGH data. Biostatistics (2005) 2.86
Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J Natl Cancer Inst (2004) 2.79
Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. J Clin Invest (2013) 2.77
Beta2-microglobulin as a biomarker in peripheral arterial disease: proteomic profiling and clinical studies. Circulation (2007) 2.72
Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Oncol (2011) 2.50
Treatment of breast cancer during pregnancy: an observational study. Lancet Oncol (2012) 2.38
Chapter 8: Screening for cervical cancer in developing countries. Vaccine (2006) 2.35
Distinct and non-redundant roles of microglia and myeloid subsets in mouse models of Alzheimer's disease. J Neurosci (2011) 2.31
Sample classification from protein mass spectrometry, by 'peak probability contrasts'. Bioinformatics (2004) 2.28
The relationship between human papillomavirus status and other molecular prognostic markers in head and neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys (2009) 2.26
A randomized, double-blinded, placebo-controlled phase II trial of recombinant human leukemia inhibitory factor (rhuLIF, emfilermin, AM424) to prevent chemotherapy-induced peripheral neuropathy. Clin Cancer Res (2005) 2.24
Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer (2011) 2.09
Characterizing the admixed African ancestry of African Americans. Genome Biol (2009) 2.01
Epithelial mesenchymal transition and cancer stem cell-like phenotypes facilitate chemoresistance in recurrent ovarian cancer. Curr Cancer Drug Targets (2010) 1.91
Genome-wide association study identifies a common variant associated with risk of endometrial cancer. Nat Genet (2011) 1.84
Laparoscopy-assisted vaginal hysterectomy compared with abdominal hysterectomy in clinical stage I endometrial cancer: safety, recurrence, and long-term outcome. Am J Obstet Gynecol (2007) 1.80
Metabolic tumor volume predicts for recurrence and death in head-and-neck cancer. Int J Radiat Oncol Biol Phys (2009) 1.71
Endometriosis and the development of malignant tumours of the pelvis. A review of literature. Best Pract Res Clin Obstet Gynaecol (2004) 1.66
Ovarian cancer. Crit Rev Oncol Hematol (2006) 1.64
The prostate cancer risk calculator from the Prostate Cancer Prevention Trial underestimates the risk of high grade cancer in contemporary referral patients. J Urol (2010) 1.50
A new prognostic model for FIGO stage 1 epithelial ovarian cancer. Gynecol Oncol (2006) 1.43
Pseudomyxoma peritonei associated with a mucinous ovarian tumor arising from a mature cystic teratoma. A case report. Int J Gynecol Pathol (2006) 1.40
LRP1B deletion in high-grade serous ovarian cancers is associated with acquired chemotherapy resistance to liposomal doxorubicin. Cancer Res (2012) 1.39
Synthesis, antimicrobial and antiviral evaluation of substituted imidazole derivatives. Eur J Med Chem (2008) 1.36
Chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning in breast cancer patients. Hum Brain Mapp (2011) 1.31
Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence. Blood (2012) 1.31
Role of integrin receptors for fibronectin, collagen and laminin in the regulation of ovarian carcinoma functions in response to a matrix microenvironment. Clin Exp Metastasis (2005) 1.30
An approach to remove albumin for the proteomic analysis of low abundance biomarkers in human serum. Proteomics (2003) 1.30
The classification of a uterine sarcoma as 'high-grade endometrial stromal sarcoma' should be abandoned. Gynecol Oncol (2004) 1.29
Pathology and physiopathology of adenomyosis. Best Pract Res Clin Obstet Gynaecol (2006) 1.29
Debilitating musculoskeletal pain and stiffness with letrozole and exemestane: associated tenosynovial changes on magnetic resonance imaging. Breast Cancer Res Treat (2006) 1.26
Nomogram to predict the probability of relapse in patients diagnosed with borderline ovarian tumors. Int J Gynecol Cancer (2013) 1.25
Intratumoral immunization: a new paradigm for cancer therapy. Clin Cancer Res (2014) 1.24
Signature patterns of gene expression in mouse atherosclerosis and their correlation to human coronary disease. Physiol Genomics (2005) 1.22
Estrogen receptor-negative invasive breast cancer: imaging features of tumors with and without human epidermal growth factor receptor type 2 overexpression. Radiology (2008) 1.21
Stathmin overexpression identifies high-risk patients and lymph node metastasis in endometrial cancer. Clin Cancer Res (2011) 1.19
Enhancing the T-cell stimulatory capacity of human dendritic cells by co-electroporation with CD40L, CD70 and constitutively active TLR4 encoding mRNA. Mol Ther (2008) 1.19
Lymphatic invasion in cutaneous melanoma is associated with sentinel lymph node metastasis. J Cutan Pathol (2008) 1.18
Hormone receptor loss in endometrial carcinoma curettage predicts lymph node metastasis and poor outcome in prospective multicentre trial. Eur J Cancer (2013) 1.17
Does estrogen receptor negative/progesterone receptor positive breast carcinoma exist? J Clin Oncol (2008) 1.17
Tree-structured supervised learning and the genetics of hypertension. Proc Natl Acad Sci U S A (2004) 1.17
Hansch analysis of substituted benzoic acid benzylidene/furan-2-yl-methylene hydrazides as antimicrobial agents. Eur J Med Chem (2008) 1.17
Messenger RNA-electroporated dendritic cells presenting MAGE-A3 simultaneously in HLA class I and class II molecules. J Immunol (2004) 1.16
CD83 expression on dendritic cells and T cells: correlation with effective immune responses. Eur J Immunol (2007) 1.15
Management of borderline ovarian neoplasms. J Clin Oncol (2007) 1.15
Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX adjuvant in women with cervical intraepithelial neoplasia. Vaccine (2004) 1.12
Acute rejection and cardiac allograft vascular disease is reduced by suppression of subclinical cytomegalovirus infection. Transplantation (2006) 1.11
Therapeutic vaccination with an autologous mRNA electroporated dendritic cell vaccine in patients with advanced melanoma. J Immunother (2011) 1.11
Cancerous ovarian stem cells: obscure targets for therapy but relevant to chemoresistance. J Cell Biochem (2013) 1.10
Whole-body MRI with diffusion-weighted sequence for staging of patients with suspected ovarian cancer: a clinical feasibility study in comparison to CT and FDG-PET/CT. Eur Radiol (2013) 1.09
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up. Int J Gynecol Cancer (2016) 1.06
First-line therapy in ovarian cancer trials. Int J Gynecol Cancer (2011) 1.03
Chemotherapy for recurrent cervical cancer. Gynecol Oncol (2007) 1.03
Sex differences in the prevalence of peripheral artery disease in patients undergoing coronary catheterization. Vasc Med (2010) 1.03
Pontocerebellar hypoplasia type 6: A British case with PEHO-like features. Am J Med Genet A (2010) 1.02
Attributes of Oct4 in stem cell biology: perspectives on cancer stem cells of the ovary. J Ovarian Res (2012) 1.02
Genome-wide association study identifies a possible susceptibility locus for endometrial cancer. Cancer Epidemiol Biomarkers Prev (2012) 1.02
Microwave tomography of extremities: 2. Functional fused imaging of flow reduction and simulated compartment syndrome. Phys Med Biol (2011) 1.01
The impact of PET/CT in the management of recurrent ovarian cancer. Gynecol Oncol (2006) 1.00
Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients. Clin Cancer Res (2009) 1.00
Single coronary artery. J Am Coll Cardiol (2009) 1.00
Mouse strain-specific differences in vascular wall gene expression and their relationship to vascular disease. Arterioscler Thromb Vasc Biol (2004) 0.99
Microwave tomography of extremities: 1. Dedicated 2D system and physiological signatures. Phys Med Biol (2011) 0.99
Subjective assessment by ultrasound is superior to the risk of malignancy index (RMI) or the risk of ovarian malignancy algorithm (ROMA) in discriminating benign from malignant adnexal masses. Eur J Cancer (2012) 0.99
Qualitative assessment of the progesterone receptor and HER2 improves the Nottingham Prognostic Index up to 5 years after breast cancer diagnosis. J Clin Oncol (2010) 0.98
Progesterone receptor gene variants and risk of endometrial cancer. Carcinogenesis (2010) 0.98
Side-by-side comparison of lentivirally transduced and mRNA-electroporated dendritic cells: implications for cancer immunotherapy protocols. Mol Ther (2004) 0.98
Two-step oligoclonal development of male germ cells. Proc Natl Acad Sci U S A (2008) 0.98
Association between HER-2/neu and the progesterone receptor in oestrogen-dependent breast cancer is age-related. Breast Cancer Res Treat (2005) 0.97
Axillary lymph node status of operable breast cancers by combined steroid receptor and HER-2 status: triple positive tumours are more likely lymph node positive. Breast Cancer Res Treat (2008) 0.97
Development of an internet-based protocol to facilitate randomized clinical trials in pediatric surgery. J Pediatr Surg (2002) 0.97
Malignant transformation within ovarian dermoid cysts: an audit of treatment received and patient outcomes. an Australia New Zealand gynaecological oncology group (ANZGOG) and gynaecologic cancer intergroup (GCIG) study. Int J Gynecol Cancer (2010) 0.96
A CpG-loaded tumor cell vaccine induces antitumor CD4+ T cells that are effective in adoptive therapy for large and established tumors. Blood (2010) 0.96
Wilms' Tumor Gene 1 (WT1)--loaded dendritic cell immunotherapy in patients with uterine tumors: a phase I/II clinical trial. Anticancer Res (2013) 0.96
Neuroendocrine and behavioral effects of embryonic exposure to endocrine disrupting chemicals in birds. Brain Res Rev (2007) 0.95
Neoadjuvant chemotherapy in advanced ovarian cancer: On what do we agree and disagree? Gynecol Oncol (2012) 0.95
Melan-A/MART-1-specific CD4 T cells in melanoma patients: identification of new epitopes and ex vivo visualization of specific T cells by MHC class II tetramers. J Immunol (2006) 0.94
Association between alphavbeta6 integrin expression, elevated p42/44 kDa MAPK, and plasminogen-dependent matrix degradation in ovarian cancer. J Cell Biochem (2002) 0.93
Epitope and HLA-type independent monitoring of antigen-specific T-cells after treatment with dendritic cells presenting full-length tumor antigens. J Immunol Methods (2012) 0.93
Selective resistance of CD44hi T cells to p53-dependent cell death results in persistence of immunologic memory after total body irradiation. J Immunol (2011) 0.92
Robotic retroperitoneal lower para-aortic lymphadenectomy in cervical carcinoma: first report on the technique used in 5 patients. Acta Obstet Gynecol Scand (2008) 0.92
Mapping the immunosuppressive environment in uterine tumors: implications for immunotherapy. Cancer Immunol Immunother (2014) 0.92
CD137 is expressed in follicular dendritic cell tumors and in classical Hodgkin and T-cell lymphomas: diagnostic and therapeutic implications. Am J Pathol (2012) 0.90
Active and passive immunotherapy for lymphoma: proving principles and improving results. J Clin Oncol (2011) 0.90
Viable cervical pregnancy with levonorgestrel containing intrauterine device, treated successfully with methotrexate and mifepristone. Eur J Obstet Gynecol Reprod Biol (2005) 0.90
Candidate locus analysis of the TERT-CLPTM1L cancer risk region on chromosome 5p15 identifies multiple independent variants associated with endometrial cancer risk. Hum Genet (2014) 0.89
Intraperitoneal chemotherapy in patients with advanced ovarian cancer: the con view. Oncologist (2008) 0.89
Immunological response after WT1 mRNA-loaded dendritic cell immunotherapy in ovarian carcinoma and carcinosarcoma. Anticancer Res (2013) 0.89
Immunomodulating antibodies and drugs for the treatment of hematological malignancies. Cancer Metastasis Rev (2011) 0.88